PLN-1474 / Pliant Therapeutics - LARVOL DELTA

The dual integrin inhibitor Bexotegrast, indicated for idiopathic pulmonary fibrosis, shows a anti-fibrotic phenotype in human MASH liver spheroids (EASL 2026) - "Human-derived 3D spheroid models serve as cost-effective and predictive tools for identifying successful anti-fibrotic drug candidates. Bexotegrast (PLN-74809) and PLN-1474, repurposed from ongoing idiopathic pulmonary fibrosis (IPF) trials, demonstrated promising anti-fibrotic effects in human MASH liver spheroids."

Fibrosis • Hepatology • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Metabolic Dysfunction-Associated Steatohepatitis • Pulmonary Disease • Respiratory Diseases • TGFB1 • TIMP1

Screening and comparison of current clinical candidates in MASH using human 3D liver spheroids (EASL-ILC 2024) - "Examples of successful translational effect are the FASN inhibitor TVB2640 (Sagimet) showing a significant reduction of triglycerides and the alphav/beta1 integrin inhibitor (PLN-1474) demonstrating a strong reduction of PC-1 secreted levels. We show for the first time a screening platform that combines safety and MASH efficacy readouts. We show the translational capacity of this human in-vitro 3D platform by recapitulating the clinical effects of several drug candidates."

Clinical • Late-breaking abstract • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Dysfunction-Associated Steatohepatitis